We are delighted to share that Antibody Analytics is shortlisted for Scotland’s Life Sciences Business Leadership Award 2024! Notably, we are the only finalist in this category who entered as a team. 

“Thrilled and honoured”

Scotland’s Life Sciences Annual Awards and Dinner celebrates the brightest stars in Scotland’s life science constellation. The annual awards recognise individuals and organisations who have contributed most to the sector. They span 9 categories from Sustainability to Lifetime Achievement Award. 

The Business Leadership Award is presented to a business leader or management team who have advanced their company significantly. That Antibody Analytics entered as a collective rather than an individual reflects our collaborative company culture. 

Our CEO, Andy Upsall, says: 

The entire team have worked incredibly hard over the last 12 months to put Antibody Analytics on the map. It’s fantastic to be recognised for delivering service excellence to our customers across the globe. We’re looking forward to celebrating with all the nominees and hope to follow the success of other Scottish CROs.

Finalists will be judged on:

• company leadership 
• commercial success
• growth
• investment
• sustainability. 

Judges will also consider the company’s impact on the life science sector in Scotland and internationally. 

A year in the life of Antibody Analytics 

Antibody Analytics is certainly up to the task. In the past year, we have seen impressive growth. We successfully secured a multi-million-pound investment to catalyse our growth, innovation, and global impact. 

Our recent recruitment drive offers rewarding roles for the best minds in biotech. We champion ‘invest-in-youth’ initiatives in the form of modern apprenticeships and degree programmes.  

Antibody Analytics’ edge lies in innovation. Its cross-functional team of experts continue to create novel solutions like the IndEx-2 platform. Launched in 2023, it addresses the significant challenge of testing the safety and efficacy of antibody-targeted I-O therapeutics in vitro. We are the only service provider with this technology allowing the expression of one, or two, target antigens over a range of biologically relevant levels, facilitating the determination of the precise antigen density activation thresholds of targeted candidate immunotherapies and antibody-based therapeutics.  

These, combined with the emergent strategy embodied by our management team, translate Antibody Analytics’ impact globally. We help customers achieve their early drug discovery milestones faster with high quality in vitro assay services, directly contributing to the growth of the international sector. 

“Valuing agility and lean decision-making processes enable us to identify and explore new opportunities quickly. To be shortlisted as a team for the award is very special, and recognises that we operate collaboratively, united by a common vision – to provide in vitro data of the highest quality.” – Adele Hannigan, Chief Business Officer.

Indeed, 83% of our customers rate our service quality as excellent, with positive feedback on our bespoke models, flexibility, and the quality and consistency of our output. 

The year ahead

Michahaila Downie, Director of People and Finance, says: “Our substantial growth is due to our ambitious vision and the dedication of the team to see this become a reality. The NorthEdge investment means we can continue to sustain this growth and surpass it!”

We will be celebrating at the Awards Dinner on Thursday the 14^th of March at the Hilton Glasgow. Cheers!